Impact of TP53 genomic alterations in LBCL treated with CD19-CAR T-cell therapy

Tumor-intrinsic features may render large B-cell lymphoma (LBCL) insensitive to CD19-directed chimeric antigen receptor T cells (CAR-T). A study of 153 adults with relapsed or refractory LBCL treated with CD19-CAR-T found that TP53 alterations (mutations and/or copy number alterations) were associated with inferior complete response and overall survival rates. The authors conclude that TP53 is a potent tumor-intrinsic biomarker that can inform risk stratification in LBCL patients treated with CD19-CAR-T.